Charles River Laboratories International (NYSE:CRL) Downgraded by William Blair to Market Perform
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday,
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...
T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara ...
In recent trading, Charles River Lbrtrs ntrntl Inc (CRL) stock price has shown some volatility, fluctuating -12.15% over the last five trades and -13.98% over the past 30 trades. This represents a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TD Cowen analysts adjusted their outlook for shares of Charles River Laboratories International Inc. (NYSE: CRL), reducing the price target from $227.00 to $182.00 while maintaining a Hold rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback